Clinical Trials | December 09, 2025
Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Valorum will advance the commercialization and distribution of Armlupeg in the United States
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
Subscribe To Our Newsletter & Stay Updated
